Compare AbbVie Inc (ABBV) vs MGM Resorts International (MGM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs MGM Resorts International — how do they compare? AbbVie Inc trades at $253.58 (market cap $449.91B), while MGM Resorts International trades at $46.38 (market cap $11.93B). The key difference: AbbVie Inc is far larger — about 37.7× MGM Resorts International's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | MGM | |
|---|---|---|
Market Cap | $449.91B | $11.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $50.69 |
52-Week Low | $184.85 | $30.72 |
Enterprise Value | $513.38B | $40.98B |
Dividend Yield | 2.72% | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
MGM Resorts International (MGM) trades at $46.64, down 0.98% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.49, slightly missing expectations, while Q4 2025 saw a significant beat. Revenue growth has been steady, reaching $17.54B in 2025, though net income margins have compressed to 1.03%. Recent news highlights a potential acquisition offer from Barry Diller at $48.30 per share, under investigation by BFA Law.
The outlook for MGM is cautiously optimistic, supported by analyst consensus leaning Buy (48.64%) and a price target of $45.45. Opportunities include strategic partnerships and digital expansion via BetMGM, but risks persist from high debt levels, regulatory scrutiny, and volatile earnings performance. Investors should weigh the acquisition premium against fundamental valuation metrics like a high P/E of 64.22.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
